Titre :

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.

Auteur(s) :

Rossi, Cédric [Auteur]
Lipides - Nutrition - Cancer [Dijon - U1231] [LNC]
André, Marc [Auteur]
Université Catholique de Louvain = Catholic University of Louvain [UCL]
Dupuis, Jehan [Auteur]
CHU Henri Mondor [Créteil]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Joly, Bertrand [Auteur]
Centre Hospitalier Sud Francilien
Lazarovici, Julien [Auteur]
Université Paris-Saclay
Ghesquières, Hervé [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Stamatoullas, Aspasia [Auteur]
Service d'hématologie [CRLCC Henri Becquerel]
Nicolas-Virelizier, Emmanuelle [Auteur]
Centre Léon Bérard [Lyon]
Feugier, Pierre [Auteur]
Centre Hospitalier Universitaire de Nancy [CHU Nancy]
Gac, Anne-Claire [Auteur]
Institut d'Hématologie de Basse-Normandie [IHBN]
Moatti, Hannah [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Fornecker, Luc-Matthieu [Auteur]
Centre Hospitalier Universitaire [Strasbourg] [CHU Strasbourg]
Deau, Bénédicte [Auteur]
Hôpital Cochin [AP-HP]
Joubert, Clémentine [Auteur]
The Lymphoma Academic Research Organisation [Lyon] [LYSARC]
Fortpied, Catherine [Auteur]
European Organisation for Research and Treatment of Cancer [Bruxelles] [EORTC]
Raemaekers, John [Auteur]
Federico, Massimo [Auteur]
Kanoun, Salim [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Meignan, Michel [Auteur]
CHU Henri Mondor [Créteil]
Traverse-Glehen, Alexandra [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Cottereau, Anne-Segolène [Auteur]
Hôpital Cochin [AP-HP]
Casasnova, René-Olivier [Auteur]
Lipides - Nutrition - Cancer [Dijon - U1231] [LNC]

Titre de la revue :

Haematologica

Nom court de la revue :

Haematologica

Numéro :

107

Date de publication :

2022-12

ISSN :

1592-8721

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Stage IIB Hodgkin lymphoma (HL) patients, with a mediastinum-to-thorax (M/T) ratio of ≥0.33 or extranodal localization have a poor prognosis and are treated either as limited or advanced stage. We compared these two ...
Lire la suite >Stage IIB Hodgkin lymphoma (HL) patients, with a mediastinum-to-thorax (M/T) ratio of ≥0.33 or extranodal localization have a poor prognosis and are treated either as limited or advanced stage. We compared these two approaches in patients included in two randomized phase III trials enrolling previously untreated early (H10) or advanced stage HL (AHL2011). We included HL patients with Ann-Arbor stage IIB with M/T ≥0.33 or extranodal involvement enrolled in the H10 or AHL2011 trials with available positron emission tomography at baseline (PET0) and after two cycles of chemotherapy (PET2). Baseline total metabolic tumor volume (TMTV) was calculated using the 41% SUVmax method. PET2 response assessment used the Deauville score. One hundred and fourty-eight patients were eligible, including 83 enrolled in the AHL2011 trial and 65 in the H10 trial. The median TMTV value was 155.5 mL (range, 8.3-782.9 mL), 165.6 mL in AHL2011 and 147 mL in H10. PET2 positivity rates were 16.9% (n=14) and 9.2% (n=6) in AHL2011 and H10 patients, respectively. With a median follow-up of 4.1 years (95% confidence interval [CI]: 3.9-4.4), overall 4-year PFS was 88.0%, 87.0% in AHL2011 and 89.2% in H10. In univariate and mutivariate analyses, baseline TMTV and PET2 response influenced significantly progression-free survival (hazard ratio [HR]=4.94, HR=3.49 respectively). Notably, among the 16 patients who relapsed, 13 (81%) had a baseline TMTV baseline ≥155 mL. Upfront ABVD plus radiation therapy or upfront escBEACOPP without radiotherapy provide similar patient’s outcome in high-risk stage IIB HL. TMTV is useful to stratify these patients at baseline.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Date de dépôt :

2023-05-25T02:38:02Z
2024-06-12T13:51:28Z